Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23881931 | 1.00 | THRB (0.46) | THRBCYP3A4CYP2C19CYP2C9KDM4E | |
| SCHEMBL3221585 | 0.94 | THRB (0.41) | THRBCYP3A4KDM4EGAAMAPT | |
| SCHEMBL5006986 | 0.88 | MTNR1A (0.37) | THRBCYP3A4CYP2C19CYP2C9 | |
| SCHEMBL5089466 | 0.88 | MTNR1A (0.37) | THRBCYP3A4CYP2C19CYP2C9 | |
| SCHEMBL5091076 | 0.88 | MTNR1A (0.37) | THRBCYP3A4CYP2C19CYP2C9 | |
| SCHEMBL3214409 | 0.84 | KDM4E (0.41) | THRBCYP3A4CYP2C19KDM4EGAA | |
| SCHEMBL11275440 | 0.82 | MTNR1A (0.49) | THRBKDM4EGAAMAPTEPHX1 | |
| SCHEMBL2634531 | 0.78 | — | — | |
| SCHEMBL28268650 | 0.78 | MTNR1A (0.53) | THRBCYP2C9GAAMAPTSMN1; SMN2 | |
| SCHEMBL28932499 | 0.78 | MTNR1A (0.53) | CYP2C19SMN1; SMN2RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| EP-4277893-A1 | INDOLE DERIVATIVES AS KINASE INHIBITORS | GB005, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230174481-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2022155111-A1 | INDOLE DERIVATIVES AS KINASE INHIBITORS | GB005, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| EP-3997080-A1 | BCAT MODULATION | Icagen, LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20210308140-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| US-20210284637-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2021-09-16 | — | — | US | disclosed |
| EP-2922859-B1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | UNIV CORK (IE) | 2021-05-05 | — | — | EP | disclosed |
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | Synchronicity Pharma, Inc. | 2013-11-14 | — | — | US | disclosed |
| WO-2013170186-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| EP-2654748-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130261125-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-10-03 | — | — | US | disclosed |
| US-20130137733-A1 | Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8404682-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8394805-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| WO-2013025882-A2 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012087772-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | CRY1, CRY2, CRYAB | THRB 911/4885CYP3A4 141/4885CYP2C19 180/4885 |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | THRB 4199/4885CYP3A4 2248/4885CYP2C19 2677/4885 |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | THRB 3653/4885CYP3A4 1926/4885CYP2C19 1607/4885 |
| US-20210284637-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | THRB 3653/4885CYP3A4 1926/4885CYP2C19 1607/4885 |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | DRD2, DRD3, GAP43 | THRB 451/4885CYP3A4 4073/4885CYP2C19 3308/4885 |
| US-20130137733-A1 | Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses | DRD2, DRD3, GAP43 | THRB 451/4885CYP3A4 4073/4885CYP2C19 3308/4885 |
| US-20210308140-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | THRB 1623/4885CYP3A4 1107/4885CYP2C19 2360/4885 |
| US-20130261125-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MAPK3, MAPK1, MAP3K1 | THRB 1062/4885CYP3A4 1226/4885CYP2C19 1223/4885 |
| US-20230174481-A1 | KINASE INHIBITORS | BTK, LYN, LCK | THRB 1591/4885CYP3A4 4419/4885CYP2C19 3190/4885 |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | THRB 3653/4885CYP3A4 1926/4885CYP2C19 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.